Overview
Leukemia in older patients presents unique challenges — the same intensive chemotherapy regimens that cure younger patients are often too toxic for elderly individuals with reduced organ reserve and comorbidities. At the same time, the biology of leukemia in older patients is frequently more adverse, with higher rates of unfavorable cytogenetics and treatment resistance. Precision medicine and immunotherapy have opened new pathways for elderly leukemia patients who were previously considered untreatable — and Shanghai is home to China's leading expert in this field.
China Medical Concierge Shanghai (CMCS) connects international patients with Shanghai's top hematology specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Leukemia in Adults & Older Patients
Types of Leukemia
- Acute myeloid leukemia (AML) — the most common acute leukemia in adults; median age at diagnosis is 68 years; prognosis worsens with age due to adverse cytogenetics and reduced treatment tolerance
- Acute lymphoblastic leukemia (ALL) — less common in older adults; Philadelphia chromosome-positive ALL (Ph+ ALL) is more frequent in older patients and requires TKI-based therapy
- Chronic myeloid leukemia (CML) — driven by BCR-ABL; highly responsive to TKIs at all ages
- Chronic lymphocytic leukemia (CLL) — the most common leukemia in older Western adults; managed with BTK inhibitors and BCL2 inhibitors
- Myelodysplastic syndromes (MDS) — pre-leukemic conditions most common in older adults; high-risk MDS requires hypomethylating agents or HSCT
Why Elderly Leukemia Requires Specialized Expertise
Older patients with leukemia face a distinct set of challenges that require specialized clinical judgment:
- Reduced treatment tolerance — intensive chemotherapy carries higher toxicity risk in older patients with reduced organ reserve
- Adverse disease biology — older AML patients have higher rates of unfavorable cytogenetics (complex karyotype, monosomal karyotype) and secondary AML from prior MDS
- Comorbidities — cardiac, renal, hepatic, and pulmonary comorbidities limit treatment options and require careful dose modification
- Geriatric assessment — functional status, cognitive function, and social support are critical determinants of treatment tolerance and outcomes
- Novel low-intensity regimens — venetoclax + azacitidine and other low-intensity combinations have transformed the treatment of older AML patients who cannot tolerate intensive chemotherapy
Common Symptoms
- Fatigue, pallor, and shortness of breath (anaemia)
- Recurrent infections (neutropenia)
- Easy bruising or bleeding (thrombocytopenia)
- Bone pain and joint pain
- Unexplained fever and night sweats
- Unexplained weight loss
Treatment: Precision Medicine & Immunotherapy for Leukemia
Precision Medicine for AML
Molecular profiling has transformed AML treatment by identifying targetable mutations that can be matched to specific therapies:
- FLT3-mutant AML — midostaurin (induction), gilteritinib (relapsed/refractory), quizartinib
- IDH1-mutant AML — ivosidenib (first-line and relapsed/refractory)
- IDH2-mutant AML — enasidenib
- NPM1-mutant AML — favorable prognosis; MRD-guided treatment decisions
- TP53-mutant AML — eprenetapopt + azacitidine; magrolimab combinations
Low-Intensity Regimens for Older/Unfit Patients
- Venetoclax + azacitidine (Ven-Aza) — the standard of care for older/unfit AML patients; complete response rates of 66% with manageable toxicity
- Azacitidine or decitabine monotherapy — for patients who cannot tolerate venetoclax combinations
- Glasdegib + low-dose cytarabine — an alternative low-intensity option
Immunotherapy for Leukemia
- Blinatumomab — bispecific T-cell engager (CD19×CD3) for relapsed/refractory B-ALL and MRD-positive ALL; highly effective in older patients who cannot tolerate intensive salvage chemotherapy
- Inotuzumab ozogamicin — CD22-targeted antibody-drug conjugate for relapsed/refractory B-ALL
- CAR-T therapy — tisagenlecleucel for relapsed/refractory B-ALL; increasingly used in older patients at experienced centers
- Magrolimab (anti-CD47) — emerging immunotherapy for AML and MDS
- PD-1/PD-L1 inhibitors — in combination with hypomethylating agents for MDS and AML
Reduced-Intensity Transplantation for Older Patients
For selected older patients with high-risk leukemia or MDS who achieve remission, reduced-intensity conditioning (RIC) allogeneic HSCT offers the potential for long-term disease control with lower transplant-related mortality than myeloablative conditioning. Patient selection and conditioning regimen optimization are critical for achieving optimal outcomes in this population.
Why Choose Ruijin Hospital for Leukemia Treatment?
- China's premier hematology center — Ruijin Hospital's Shanghai Institute of Hematology is China's most prestigious hematology research and clinical institution
- National leadership in leukemia precision medicine — comprehensive molecular profiling and targeted therapy expertise
- Specialized elderly leukemia program — China's leading expert in geriatric hematology and low-intensity leukemia treatment
- Immunotherapy expertise — blinatumomab, inotuzumab, CAR-T, and emerging immunotherapy agents
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Li Junmin — Ruijin Hospital, Shanghai Jiao Tong University
Prof. Li Junmin (李军民) is a Professor of Hematology at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine — home to the Shanghai Institute of Hematology, China's most prestigious hematology institution. He serves as Vice President of the Chinese Medical Doctor Association Hematology Branch and President of the Chinese Geriatric Medicine Society Hematology Branch — the two most senior positions in Chinese leukemia and geriatric hematology respectively.
China's Leading Expert in Elderly Leukemia
As President of the Chinese Geriatric Medicine Society Hematology Branch, Prof. Li is China's foremost authority on the treatment of blood cancers in older patients. His expertise in geriatric assessment, low-intensity treatment regimens, and immunotherapy for elderly leukemia patients — combined with his deep knowledge of leukemia precision medicine — makes him the ideal specialist for older patients who need effective treatment without the toxicity of intensive chemotherapy.
Leukemia Precision Medicine & Immunotherapy
Prof. Li's long-term research focus on leukemia precision medicine and novel immunotherapy approaches has established him as one of China's leading experts in targeted therapy and immunotherapy for leukemia. His work encompasses FLT3 and IDH inhibitors for AML, blinatumomab and inotuzumab for ALL, and emerging immunotherapy combinations — ensuring that his patients have access to the most innovative, evidence-based treatment options.
Clinical Expertise
- Acute myeloid leukemia (AML) — precision medicine, targeted therapy (FLT3, IDH1/2), and low-intensity regimens (Ven-Aza) for older patients
- Acute lymphoblastic leukemia (ALL) — including Ph+ ALL and immunotherapy (blinatumomab, inotuzumab, CAR-T)
- Elderly leukemia — geriatric assessment, low-intensity treatment, and individualized care for older patients
- Myelodysplastic syndromes (MDS) — risk stratification and treatment including hypomethylating agents and HSCT
- Leukemia immunotherapy — bispecific antibodies, ADCs, CAR-T, and emerging immunotherapy combinations
For international patients, Prof. Li's team offers remote pre-consultation review of bone marrow biopsy, cytogenetics, molecular profiling, and prior treatment records, enabling a precise risk assessment and individualized treatment plan to be developed before arrival in Shanghai.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Li Junmin and the Ruijin Hospital hematology team
- ✅ Bone marrow biopsy, cytogenetics, molecular profiling, and prior treatment record translation and pre-consultation review
- ✅ Second opinion facilitation — especially for elderly patients or those with treatment-resistant leukemia
- ✅ Clinical trial eligibility assessment
- ✅ Hospital admission and treatment scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with leukemia — particularly if you are an older patient or have treatment-resistant disease — our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0 commentaire